1. Home
  2. ONC vs GIB Comparison

ONC vs GIB Comparison

Compare ONC & GIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • GIB
  • Stock Information
  • Founded
  • ONC 2010
  • GIB 1976
  • Country
  • ONC Switzerland
  • GIB Canada
  • Employees
  • ONC N/A
  • GIB N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • GIB Professional Services
  • Sector
  • ONC Health Care
  • GIB Consumer Discretionary
  • Exchange
  • ONC Nasdaq
  • GIB Nasdaq
  • Market Cap
  • ONC 26.9B
  • GIB 24.1B
  • IPO Year
  • ONC N/A
  • GIB N/A
  • Fundamental
  • Price
  • ONC $245.58
  • GIB $107.46
  • Analyst Decision
  • ONC Strong Buy
  • GIB Buy
  • Analyst Count
  • ONC 7
  • GIB 4
  • Target Price
  • ONC $326.43
  • GIB $156.75
  • AVG Volume (30 Days)
  • ONC 368.4K
  • GIB 198.0K
  • Earning Date
  • ONC 05-07-2025
  • GIB 04-30-2025
  • Dividend Yield
  • ONC N/A
  • GIB 0.31%
  • EPS Growth
  • ONC N/A
  • GIB 8.72
  • EPS
  • ONC N/A
  • GIB 5.30
  • Revenue
  • ONC $4,180,740,829.00
  • GIB $10,533,984,064.00
  • Revenue This Year
  • ONC $32.78
  • GIB $11.12
  • Revenue Next Year
  • ONC $19.07
  • GIB $4.86
  • P/E Ratio
  • ONC N/A
  • GIB $19.63
  • Revenue Growth
  • ONC 52.09
  • GIB 4.60
  • 52 Week Low
  • ONC $141.31
  • GIB $92.85
  • 52 Week High
  • ONC $287.88
  • GIB $122.79
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • GIB 54.67
  • Support Level
  • ONC N/A
  • GIB $106.89
  • Resistance Level
  • ONC N/A
  • GIB $108.55
  • Average True Range (ATR)
  • ONC 0.00
  • GIB 1.26
  • MACD
  • ONC 0.00
  • GIB -0.13
  • Stochastic Oscillator
  • ONC 0.00
  • GIB 49.03

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About GIB CGI Inc.

CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company generates more than CAD 14 billion in annual revenue, employs over 90,000 personnel, and operates across 400 offices in 40 countries. CGI offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services. Its largest vertical market is government, which contributes more than a third of group revenue.

Share on Social Networks: